Literature DB >> 25604469

Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide.

Jérôme Avouac1, Christophe Meune2, Camille Chenevier-Gobeaux3, Didier Borderie3, Guillaume Lefevre4, André Kahan5, Yannick Allanore1.   

Abstract

OBJECTIVE: To measure plasma concentrations of high-sensitivity cardiac troponin T (HS-cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with systemic sclerosis (SSc; scleroderma) and age- and sex-matched healthy control subjects, and to examine the contribution of traditional cardiovascular risk factors and SSc features to the concentrations of these 2 cardiac biomarkers.
METHODS: Plasma HS-cTnT and NT-proBNP concentrations were measured using the electrochemiluminescence method and sandwich immunoassay, respectively.
RESULTS: The study group comprised 161 unrelated patients with SSc and 213 matched control subjects. HS-cTnT and NT-proBNP plasma levels were significantly increased in SSc patients compared with controls (both P < 0.001). Similar results were observed in the subgroup of patients with SSc who had no cardiovascular risk factors (n = 72). Multivariate logistic regression analysis confirmed diabetes mellitus (P = 0.006), high blood pressure (P = 0.021), precapillary pulmonary hypertension (P = 0.039), and the diffuse cutaneous SSc (P = 0.004) as factors independently associated with an HS-cTnT level of >14 ng/liter. Increased NT-proBNP concentrations were associated only with the presence of precapillary pulmonary hypertension (P < 0.001). Normal concentrations of both HS-cTnT and NT-proBNP had a high negative predictive value for precapillary pulmonary hypertension (92%), and the combination of increased values of these 2 markers had the highest strength of association with precapillary pulmonary hypertension in logistic regression analysis.
CONCLUSION: HS-cTnT and NT-proBNP concentrations are increased in patients with SSc, even in those who are free of cardiovascular risk factors. These easily obtained biomarkers may be useful for systematic evaluation and stratification of SSc patients, especially to identify those at risk of pulmonary hypertension.
© 2015 American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25604469     DOI: 10.1002/acr.22547

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  18 in total

1.  Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis.

Authors:  Raluca B Dumitru; Lesley-Anne Bissell; Bara Erhayiem; Graham Fent; Ananth Kidambi; Peter Swoboda; Giuseppina Abignano; Helena Donica; Agata Burska; John P Greenwood; John Biglands; Francesco Del Galdo; Sven Plein; Maya H Buch
Journal:  Rheumatology (Oxford)       Date:  2021-06-18       Impact factor: 7.580

Review 2.  Points to consider when doing a trial primarily involving the heart.

Authors:  Yannick Allanore; Oliver Distler; Ulrich A Walker; Dinesh Khanna; Daniel E Furst; Christophe Meune
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

3.  Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

Authors:  Amber Young; Vivek Nagaraja; Mark Basilious; Mirette Habib; Whitney Townsend; Heather Gladue; David Badesch; J Simon R Gibbs; Deepa Gopalan; Alessandra Manes; Ronald Oudiz; Toru Satoh; Adam Torbicki; Fernando Torres; Vallerie McLaughlin; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2018-10-14       Impact factor: 5.532

4.  Prevalence of high-sensitivity cardiac troponin T in real-life cohorts of psoriatic arthritis and general population: a cross-sectional study.

Authors:  Victoria Furer; Shani Shenhar-Tsarfaty; Shlomo Berliner; Uri Arad; Daphna Paran; Inna Mailis; Ori Rogowski; David Zeltser; Itzhak Shapira; Hagit Matz; Ori Elkayam
Journal:  Rheumatol Int       Date:  2019-10-23       Impact factor: 2.631

Review 5.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

6.  NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group.

Authors:  Mayank Jha; Mianbo Wang; Russell Steele; Murray Baron; Marvin J Fritzler; Marie Hudson
Journal:  J Scleroderma Relat Disord       Date:  2021-09-03

Review 7.  Update on assessment and management of primary cardiac involvement in systemic sclerosis.

Authors:  Vasiliki-Kalliopi Bournia; Christos Tountas; Athanase D Protogerou; Stylianos Panopoulos; Sophie Mavrogeni; Petros P Sfikakis
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

Review 8.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

9.  Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions.

Authors:  Jison Hong; David J Maron; Tsuyoshi Shirai; Cornelia M Weyand
Journal:  Int J Clin Rheumtol       Date:  2015-10

10.  An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Authors:  Murray Baron; Bashar Kahaleh; Elana J Bernstein; Lorinda Chung; Philip J Clements; Christopher Denton; Robyn T Domsic; Nava Ferdowsi; Ivan Foeldvari; Tracy Frech; Jessica K Gordon; Marie Hudson; Sindhu R Johnson; Dinesh Khanna; Zsuzsannah McMahan; Peter A Merkel; Sonali Narain; Mandana Nikpour; John D Pauling; Laura Ross; Antonia Maria Valenzuela Vergara; Alessandra Vacca
Journal:  J Scleroderma Relat Disord       Date:  2018-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.